AZD5335 + Itraconazole
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fallopian Tube Cancer
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal
Trial Timeline
Jan 26, 2026 → Oct 22, 2027
NCT ID
NCT07402915About AZD5335 + Itraconazole
AZD5335 + Itraconazole is a phase 1 stage product being developed by AstraZeneca for Fallopian Tube Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07402915. Target conditions include Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal.
What happened to similar drugs?
0 of 4 similar drugs in Fallopian Tube Cancer were approved
Approved (0) Terminated (2) Active (2)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07402915 | Phase 1 | Recruiting |
Competing Products
20 competing products in Fallopian Tube Cancer